IRhythm Technologies Inc. has announced the publication of a large-scale clinical study in the journal Heart Rhythm, featuring real-world data from more than 1.1 million patients who used the company's Zio® long-term continuous monitoring (LTCM) service. The study found that short-term (24-48-hour) monitoring may miss actionable arrhythmias, even in patients reporting daily symptoms, and that patient-reported symptoms were infrequently associated with arrhythmia events. These results highlight the potential value of long-term continuous monitoring. In addition, data from over 742,000 patients were presented at the American Heart Association (AHA) Scientific Sessions 2025, demonstrating that at-home self-application and activation of Zio 14-day patch-based LTCM devices achieved high compliance, strong engagement, and data quality comparable to in-clinic application. Further analyses presented at AHA 2025 provided expanded insights into CKM/CKD risk and supported earlier arrhythmia detection in at-risk populations. IRhythm's ongoing collaboration with Lucem Health was also noted, aiming to combine ECG monitoring with AI-powered risk stratification to more precisely identify individuals at risk for arrhythmias. Early pilot testing from this collaboration suggests potential improvements in targeting at-risk populations and enabling earlier clinical engagement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRhythm Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573045-en) on November 11, 2025, and is solely responsible for the information contained therein.
Comments